Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

‘Pharmaceutical’ Controls, Lower Costs: Future Of Cannabinoid Ingredients In Biosynthesis?

Feb 26 2021

• By Malcolm Spicer

Related Content

CBD Market Provides ‘Enormous Incentive’ For FDA's Regulatory Answer But Decision Remains TBD

Dec 10 2020

Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking

Aug 04 2020

CBD Regulation Bill Filed In US House Again; VMS In Pre-Tax Savings Accounts In First Senate Vote

Feb 05 2021

Biden Administration Pause On Pending Trump-Era Rules Stalls FDA Cannabinoids Guidance Progress

Jan 27 2021

In Rare Cannabinoids, BioMedican Sees Alphabet Of Potential Dietary And Drug Ingredients

Feb 26 2021

Additional Topics

International United States US States Cannabidiol CBD Dietary Supplements Research & Development Advertising, Marketing & Sales Business Strategies Commercial Companies Compliance Distribution Enforcement FDA Ingredients Manufacturing OTC Drugs Policy Regulation Consumer

More from Cannabis/CBD

More from Ingredients & Safety

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window